Plate Nº 36 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Only 3% of Medicaid Youth With Opioid Disorder Stay on Medication
Only 3.1% of 229,847 Medicaid-enrolled youths with opioid use disorder stayed on medication for 180 days, a new JAMA Network Open study finds.
By Marcus Bennett3 min read621 words
In brief
- Only 3.1% of Medicaid-enrolled youths with opioid use disorder stayed on medication for 180 days or more.
- The study analyzed eight years of data covering 229,847 people aged 13 to 25.
- 50.7% initiated treatment within 14 days of diagnosis; 32.9% engaged in continued care.
- Results were published in JAMA Network Open (2026), DOI: 10.1001/jamanetworkopen.2026.37263.
- Younger adolescents and racially minoritized youths showed consistently lower progression through care stages.
Only 3.1% of Medicaid-enrolled adolescents and young adults with opioid use disorder were still taking medication after 180 days, according to a new study published in JAMA Network Open. That six-month mark matters: researchers and clinicians treat it as a key quality-of-care measure, because longer treatment is linked to better outcomes.
The study, conducted by investigators at Mass General Brigham, tracked 229,847 people aged 13 to 25 diagnosed with opioid use disorder, using eight years of national insurance claims data. The numbers describe a care pipeline that narrows sharply at every stage:
- 50.7% started treatment within 14 days of diagnosis.
- 32.9% engaged in care, meaning they attended two or more additional sessions in the 34 days after starting.
- 46.3% of those engaged in treatment began medication.
- One in 32 — 3.1% — continued medication for at least 180 days.
The context makes these figures urgent. Roughly one in 100 adolescents and young adults in the United States has opioid use disorder, and fatal overdoses in this age group have climbed sharply since 2019 as fentanyl spread through the drug supply.
"Untreated opioid use disorder in young people has both immediate and lifelong consequences, and overdoses and poisonings have become a leading cause of death in this age group," said lead author Scott Hadland, M.D., M.P.H., chief of adolescent and young adult medicine at Mass General Brigham for Children. "Our findings suggest large gaps in care that are keeping this population vulnerable to premature death and poor health outcomes."
What do the findings actually show?
Opioid use disorder is a medical condition in which a person cannot stop using opioids despite harm. Effective treatment exists, and medications are considered the foundation of evidence-based care. The study focused on three: buprenorphine, methadone and extended-release naltrexone — drugs that reduce cravings and withdrawal and lower the risk of overdose death.
The researchers measured how young people move through what clinicians call the "stages of care": diagnosis, initiation, engagement, medication start and retention. The data show that attrition is severe at every step, and that half of diagnosed youths never begin treatment at all.
Who falls through the cracks?
The gaps are not evenly distributed. Younger adolescents and racially minoritized youths progressed through the stages of care at consistently lower rates than their peers. In other words, the young people who most need reliable treatment are often the least likely to receive and keep it.
The study's design carries limitations. It relies on insurance claims, which record billed services rather than the full picture of a patient's health or circumstances. Claims data cannot capture why someone stopped treatment — whether because of access barriers, stigma, provider behavior or personal choice.
Why does this matter for policy?
The study population is Medicaid-enrolled, meaning the findings speak directly to the public insurance program that covers a large share of young Americans. Before this work, the researchers note, little was known about how youths progress through the stages of treatment for opioid use disorder.
"What we found is essential to inform Medicaid plan design, service delivery and policies to improve quality and equity in youth opioid use disorder care," Hadland said.
The findings suggest that simply diagnosing the disorder is not enough. If retention on medication — the stage most strongly tied to survival — reaches only about one patient in 32, the health system is losing most young people somewhere along the way. The authors point to Medicaid plan design and service delivery as levers that could close those gaps.
The study, "Opioid Use Disorder and Evidence-Based Care Among Medicaid-Enrolled Youths," appears in JAMA Network Open (2026), DOI: 10.1001/jamanetworkopen.2026.37263.
via Medical Xpress (Source)
More from Marcus Bennett
Nearby plates
- 29% Off Opioids After One Year: Support Program Could Be NHS Value
- Cychlorphine: A New Opioid Up to 10 Times Stronger Than Fentanyl
- NIDA Trial Supports Weekly Buprenorphine in Pregnancy
- US Medical Cannabis Registrations Jumped 420% From 2016 to 2024
- Alzheimer's Drug Matches Trial Results in Real-World Patients